Operating Cash Flow per Share: A measure of financial performance calculated as operating cash flow, expressed on a per share basis. Calculated as: Cash Flow from Operations / Weighted Average Shares Outstanding (Diluted)
CRISPR Therapeutics AG (CRSP) had Operating Cash Flow per Share of $-1.69 for the most recently reported fiscal quarter, ending 2024-12-31.
| Income Statement Financials | |
$35.69M |
|
$-37.31M |
|
-- |
|
$35.69M |
|
$100.28M |
|
$-64.59M |
|
$27.98M |
|
$-36.61M |
|
$-36.61M |
|
$-37.31M |
|
$-37.31M |
|
$-37.31M |
|
$-37.31M |
|
$-64.59M |
|
$-59.75M |
|
84.36M |
|
84.36M |
|
$-0.41 |
|
$-0.41 |
|
| Balance Sheet Financials | |
$1.94B |
|
$134.09M |
|
$304.90M |
|
$2.24B |
|
$87.78M |
|
-- |
|
$222.17M |
|
$309.95M |
|
$1.93B |
|
$1.93B |
|
$1.93B |
|
85.74M |
|
| Cash Flow Statement Financials | |
$-142.77M |
|
$-280.48M |
|
$331.98M |
|
$401.07M |
|
$309.78M |
|
$-91.29M |
|
$86.57M |
|
-- |
|
-- |
|
| Fundamental Metrics & Ratios | |
22.07 |
|
-- |
|
-- |
|
-- |
|
-- |
|
100.00% |
|
-180.97% |
|
-180.97% |
|
-- |
|
-102.58% |
|
-104.54% |
|
$-144.68M |
|
-- |
|
-- |
|
-- |
|
0.02 |
|
-- |
|
1.43 |
|
63.04 |
|
-1.93% |
|
-1.93% |
|
-1.66% |
|
-1.93% |
|
$22.53 |
|
$-1.72 |
|
|
Operating Cash Flow per Share |
$-1.69 |